生物股份(600201) - 2016 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 20.09% to CNY 485,122,863.38 for the year-to-date period[7] - Operating income for the year-to-date period increased by 16.58% to CNY 1,032,971,707.46[7] - Basic earnings per share increased by 18.06% to CNY 0.85[7] - Total operating revenue for Q3 2016 reached ¥412,749,851.97, a 25.8% increase from ¥328,170,585.47 in Q3 2015[26] - Net profit for Q3 2016 was ¥200,771,458.64, representing a 27.3% increase compared to ¥157,654,735.01 in Q3 2015[28] - The total profit for the first nine months was ¥482,599,390.83, up from ¥373,764,931.65 in the same period last year, reflecting a year-on-year increase of 29.1%[30] Assets and Liabilities - Total assets increased by 59.74% to CNY 4,073,814,680.53 compared to the end of the previous year[7] - Current assets reached CNY 3,019,842,115.75, a significant increase from CNY 1,542,600,445.10 at the start of the year, reflecting a growth of about 95.7%[20] - The company's total liabilities amounted to CNY 483,033,069.31, slightly up from CNY 481,624,136.55 at the beginning of the year, indicating a marginal increase of about 0.3%[21] - Total liabilities as of the end of Q3 2016 amounted to ¥205,712,008.83, compared to ¥264,537,248.16 at the end of Q3 2015[24] - Shareholders' equity increased to CNY 3,590,781,611.22 from CNY 2,068,595,782.03, representing a growth of approximately 73.6%[21] Cash Flow - Cash flow from operating activities surged by 451.49% to CNY 329,450,454.69 compared to the same period last year[7] - Cash received from operating activities increased by CNY 289.66 million, a rise of 50.16%, attributed to increased collections from direct sales in the biopharmaceutical sector[14] - Cash inflow from financing activities was CNY 1,225,999,980.00, significantly higher than CNY 14,750,400.00 in the same period last year[34] - The net increase in cash and cash equivalents for the period was CNY 144,305,230.05, compared to a decrease of CNY 38,581,611.75 last year[35] Investments - Long-term equity investments increased by CNY 49.87 million, up 49.93%, due to investments in Beijing Zhongji Huake Venture Capital Partnership[12] - The company plans to invest CNY 50 million in equity investment in Beijing Zhongji Huake Venture Capital Partnership[16] - The company reported a government subsidy of CNY 2,839,400.00 for the year-to-date period[8] Shareholder Information - The number of shareholders reached 19,285 by the end of the reporting period[9] - The top shareholder, Inner Mongolia Agricultural and Animal Husbandry Pharmaceutical Co., Ltd., holds 10.96% of shares[9] Operating Costs - Operating costs increased by CNY 33.33 million, a rise of 15.76%, corresponding to the increase in vaccine sales[14] - The company's management expenses for the first nine months were ¥30,071,477.39, down from ¥45,601,246.03 in the same period last year, showing a reduction of 34.1%[30] - The operating costs for the third quarter were ¥2,795,887.24, slightly down from ¥2,885,705.47 in the same period last year, indicating a decrease of 3.1%[30]